Q32 Bio reports 36-week data from SIGNAL-AA trial’s Part B in alopecia areata

Q32 Bio has reported positive 36-week top line data from Part B of the SIGNAL-AA Phase IIa trial of bempikibart for patients with severe or very severe alopecia areata. The trial enrolled 33 patients with severe or very severe forms of AA, most with baseline SALT scores between 50 and 100. SALT-20 response, defined as at least 80% scalp hair coverage, was achieved by 40.0% of the mITT group. Credit: Alona Siniehina / Shutterstock.com. Q32 Bio has reported positive 36-week top line data from Part B of the SIGNAL-AA Phase IIa trial of bempikibart for patients with severe or very…

Source: Clinical Trials Arena